



Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Hiroyuki Okuzawa, Representative Director, President and CEO
(Code no.: 4568, Prime Market, Tokyo Stock Exchange)
Please address inquiries to Ari Fujishiro, Corporate Officer,
Head of Investor Relations and Shareholder Relations Department
Telephone: for media +81-3-6225-1126
for stock market participants +81-3-6225-1125

Daiichi Sankyo Receives Favorable Judgment in Damage Claim Filed by NTK

Tokyo, Japan (September 10, 2026) – As previously announced in the press release dated November 22, 2023*, entitled “Daiichi Sankyo’s Statement Regarding NTK’s Complaint,” and May 22, 2025**, entitled “Notice Concerning Filing of Motion by NTK to Expand Claims in Lawsuit for Compensation for Damages Against Daiichi Sankyo”, Northern TK Venture Pte. Ltd. (Headquarters: Singapore; hereinafter, “NTK”), an indirect wholly-owned subsidiary of IHH Healthcare Berhad (Headquarters: Malaysia; hereinafter, “IHH”), filed a lawsuit against Daiichi Sankyo Company, Limited (Headquarters: Chuo-ku, Tokyo; hereinafter, “Daiichi Sankyo”) before the Tokyo District Court in Japan on October 16, 2023, seeking JPY20 billion in damages and other relief (hereinafter, the “Lawsuit”). Subsequently, a motion to amend the claim was filed on May 9, 2025, and NTK’s claim was expanded to JPY 203,301,807,840.

On September 10, 2026, the Tokyo District Court rendered a judgment recognizing Daiichi Sankyo’s arguments and dismissing all of NTK’s claims. The Company hereby announces the judgment.

*https://www.daiichisankyo.com/files/news/pressrelease/pdf/202311/20231122_E.pdf

** https://www.daiichisankyo.com/files/news/pressrelease/pdf/202505/20250522_E.pdf

1. Court Where Lawsuit Was Filed and Relevant Dates
 - (1) Court where the lawsuit was filed: Tokyo District Court
 - (2) Date of the filing: October 16, 2023 (date of the service of the complaint: November 13, 2023)
 - (3) Date of the filing of the motion to amend the claim: May 9, 2025 (date of the service of the motion to amend: May 20, 2025)
 - (4) Date of the Judgement: September 10, 2026
2. Overview of Plaintiff

Name: Northern TK Venture Pte. Ltd.
Location: 1, HARBOURFRONT PLACE, #03-02, HARBOURFRONT TOWER ONE, Singapore 098633

Name and title of representative: Agarwal Aanchal, Representative Director

3. Cause of Lawsuit and Proceedings Leading to Judgment

Based on an arbitral award dated April 29, 2016 against former shareholders of Ranbaxy (hereinafter, "Arbitration Award"), Daiichi Sankyo has been pursuing enforcement of the Arbitration Award before the courts in India in accordance with Indian law. In the course of these enforcement proceedings, a tender offer by NTK for Fortis Healthcare Limited (hereinafter, "FHL"), was suspended pursuant to a decision by the Supreme Court of India.

NTK filed the Lawsuit alleging that it suffered damages, including the suspension of the tender offer due to the interference of Daiichi Sankyo. In response, Daiichi Sankyo has consistently asserted that NTK's allegations have no merit, and that the suspension of the tender offer resulted from a decision made by the Supreme Court of India following due process in the course of the enforcement of the Arbitration Award in India to Daiichi Sankyo.

On September 10, 2026, the Tokyo District Court accepted the arguments of Daiichi Sankyo, determined that NTK's allegations had no merit, and rendered a judgment dismissing all of NTK's claims.

4. Details of Lawsuit

(1) Details of claims

(i) Claim for damages;

(ii) Request for an injunction against interference with the acquisition of shares and other matters; and

(iii) Demand that a statement prepared by NTK be posted on Daiichi Sankyo's website and that a document containing the same statement be submitted to the Securities and Exchange Board of India (SEBI).

(2) Amount of Damage Claim

JPY 203,301,807,840

5. Details of Judgement

On September 10, 2026, in the Lawsuit, the Tokyo District Court rendered a judgment dismissing all of NTK's claims.

Daiichi Sankyo considers that this judgment recognizes the legitimacy of the Company's position and represents a fair determination.

6. Outlook

At this time, this judgment will have no impact on Daiichi Sankyo financial results. If any additional matter requiring disclosure arises in connection with this lawsuit, Daiichi Sankyo will promptly make an announcement. In addition, if NTK appeals this judgement, Daiichi Sankyo will continue to assert its position in the appellate proceedings.

About Daiichi Sankyo

Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of

contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit www.daiichisankyo.com.

MEDIA CONTACTS:

Global/Japan:

DS-PR_jp@daiichisankyo.com

INVESTOR RELATIONS CONTACT:

DaiichiSankyoIR_jp@daiichisankyo.com